Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Receivables (2016 - 2017)

Usana Health Sciences (USNA) has disclosed Receivables for 5 consecutive years, with $6.9 million as the latest value for Q3 2017.

  • Quarterly Receivables fell 6.9% to $6.9 million in Q3 2017 from the year-ago period, while the trailing twelve-month figure was $6.9 million through Jul 2017, down 6.9% year-over-year, with the annual reading at $18.5 million for FY2016, 11.17% down from the prior year.
  • Receivables for Q3 2017 was $6.9 million at Usana Health Sciences, up from $6.8 million in the prior quarter.
  • The five-year high for Receivables was $20.9 million in Q1 2016, with the low at $6.4 million in Q1 2014.
  • Average Receivables over 5 years is $9.9 million, with a median of $7.9 million recorded in 2016.
  • Peak annual rise in Receivables hit 41.6% in 2016, while the deepest fall reached 18.73% in 2016.
  • Over 5 years, Receivables stood at $10.4 million in 2013, then dropped by 29.46% to $7.4 million in 2014, then increased by 18.7% to $8.7 million in 2015, then surged by 112.09% to $18.5 million in 2016, then crashed by 62.93% to $6.9 million in 2017.
  • According to Business Quant data, Receivables over the past three periods came in at $6.9 million, $6.8 million, and $18.5 million for Q3 2017, Q2 2017, and Q4 2016 respectively.